Acelyrin Rebuffs Concentra’s Acquisition Bid, Reaffirms Commitment to Alumis Merger

Here's a Title, keywords, and key facts about Acelyrin rejecting Concentra's buyout offer in favor of merging with Alumis:

Acelyrin's Board of Directors rejected an unsolicited buyout offer from Concentra Biosciences, controlled by Tang Capital Partners1 4.

Acelyrin reaffirmed its commitment to merge with Alumis in an all-stock transaction, originally announced in February 20251 2.

The Acelyrin-Alumis merger is expected to close in Q2 2025, subject to stockholder approval and other customary conditions1 4.

Upon completion, Alumis stockholders will own 55% of the combined company, while Acelyrin stockholders will own 45%2.

The merged entity will operate under the Alumis name and be headquartered in San Francisco2.

The combined company is expected to have a pro forma cash position of approximately $737 million as of December 31, 20242 9.

This cash runway is projected to fund operations through 2027 and support the advancement of multiple clinical programs2 9.

Acelyrin's Board believes the Alumis merger maximizes long-term value for stockholders compared to Concentra's proposal4 8.

The merger aims to create a leading clinical-stage biopharmaceutical company focused on immune-mediated diseases9.

Concentra's offer included $3 per share in cash plus a contingent value right for 80% of net proceeds from potential asset sales or licensing deals3.

Sources: